49 results about "Deferoxamine" patented technology

Methods and pharmaceutical compositions for preconditioning and/or providing neuroprotection to the animal central nervous system against the effects of ischemia, trauma, metal poisoning and neurodegeneration, including the associated cognitive, behavioral and physical impairments. In one embodiment, the method is accomplished by stimulating and stabilizing hypoxia-inducible factor-1α (HIF-1α). HIF-1α is known to provide a neuroprotective benefit under ischemic conditions. Patients at risk for certain diseases or disorders that are associated with risk for cerebral ischemia may benefit, e.g., those at risk for Alzheimer's disease, Parkinson's disease, Wilson's disease or stroke or those patients having head or spinal cord injury. Patients undergoing certain medical procedures that may result in ischemia may also benefit. Initially, the possibility of ischemia or neurodegeneration is recognized. Intranasal therapeutic agents are administered to the upper third of the nasal cavity to bypass the blood-brain barrier and access the central nervous system directly to avoid unwanted and potentially lethal side effects. Therapeutic agents include those substances that interact with iron and/or copper such as iron chelators, copper chelators, and antioxidants. A particular example of such therapeutic agents is the iron chelator deferoxamine (DFO). Intranasal administration of DFO is known to stimulate and/or stabilize HIF-1α and provides an efficient and safe method for pre-conditioning the brain to protect against cerebral ischemia. Moreover, DFO is shown to decrease weight loss in subjects when administered pre and/or post stroke.

Methods and pharmaceutical compositions for preconditioning and/or providing neuroprotection to the animal central nervous system against the effects of neurological disorders involving ischemia, trauma, metal poisoning and neurodegeneration, including the associated cognitive, behavioral and physical impairments. In one embodiment, the method is accomplished by stimulating and/or stabilizing hypoxia-inducible factor-1α (HIF-1α). HIF-1α is known to provide a neuroprotective benefit under ischemic conditions. In another embodiment, the method is accomplished by differentially reducing, inhibiting or preventing the increased expression of selected genes caused by neurological disorders. Patients at risk for certain diseases or disorders that are associated with risk for cerebral ischemia may benefit, e.g., those at risk for Alzheimer's disease, Parkinson's disease, Wilson's disease, Huntington's disease, thalassemia or stroke, or those patients having head or spinal cord injury. Patients undergoing certain medical procedures that may result in ischemia may also benefit. Initially, the possibility of ischemia or neurodegeneration is recognized. Intranasal therapeutic agents are administered to the upper third of the nasal cavity to bypass the blood-brain barrier and access the central nervous system directly to avoid unwanted and potentially lethal side effects. Therapeutic agents include those substances that interact with iron and/or copper such as iron chelators, copper chelators, and antioxidants. Particular examples of such therapeutic agents are the iron chelators deferoxamine (DFO) and deferasirox. Intranasal administration of DFO is known to stimulate and/or stabilize HIF-1α and provides an efficient and safe method for pre-conditioning the brain to protect against cerebral ischemia.

The invention discloses an artificial medicine carrying coaxial regenerated intravascular stent and a compound process preparation method thereof. The intravascular stent is provided with a three-layer structure which is prepared through different process methods, an inner-layer material adopts a deferoxamine DFO+PVA core layer solution and a PCL shell layer solution, and a coaxial electrospinning forming process is adopted; a middle-layer material adopts a PVA+SA mixed solution, a dipping method forming process is adopted, and calcium chloride is adopted for cross linking after outer layer electrospinning is carried out; an outer-layer material adopts a gentamicin GS+PVA core layer solution and a PCL shell layer solution, and the coaxial electrospinning forming process is adopted. The three-layer medicine carrying intravascular stent is prepared through the two processes by compounding different materials, the three-layer structure of a natural blood vessel is simulated well, the time needed by in-vitro culture and transplantation is shortened, the success rate is increased, and the intravascular stent has wide prospects in clinical application.

The invention provides a method for dissociating iron coordination polymer nanoparticles. The method comprises the steps that the iron coordination polymer nanoparticles are dissociated by a dissociation agent which is one or more selected from a group consisting of deferoxamine, deferiprone, ethylenediamine tetraacetic acid and ethylenediamine tetraacetic acid disodium salt. The iron coordinationpolymer nanoparticles are prepared from polyphenol, trivalent iron salt and macromoleclar polymer. The special dissociation agent is adopted to dissociate the iron coordination polymer nanoparticles.Under the action of the dissociation agent, the iron coordination polymer nanoparticles can be quickly dissociated into small nanoparticles or a small molecular solution. The dissociating method canquickly remove the iron coordination polymer nanoparticles in vivo and particularly the iron coordination polymer nanoparticles at the position of the liver, and reduce potential damage to the liver.

The present invention relates to methods kits and combined compositions using DFO-metal complexes, specifically, Zinc-desferrioxamine (Zn-DFO), gallium-desferrioxamine (Ga-DFO) complexes and any combinations thereof for preventing, treating, ameliorating or inhibiting an immune-related disorder, specifically, a skin-related inflammatory disorder such as psoriasis, an inflammatory respiratory condition such as asthma, and an autoimmune disease such as diabetes and any immune-related disorder.

The invention provides a preparation method of a multifunctional electrospinning scaffold for bone regeneration. The method belongs to the field of tissue engineering and regenerative medicine, and comprises the following specific steps: 1, preparing lysophosphatidic acid nanoparticles and deferoxamine nanoparticles; 2, preparing a medical polymer mixed solution and dividing the medical polymer mixed solution into two equal parts; 3, preparing a coaxial electrospinning shell layer solution from the lysophosphatidic acid nanoparticles, zinc oxide nanoparticles and the medical polymer mixed solution; 4, preparing a coaxial electrospinning core layer solution from the deferoxamine nanoparticles and another medical polymer mixed solution; 5, preparing the electrospinning scaffold with a core-shell structure; and 6, performing vacuum drying until a solvent is removed, thereby finally obtaining the product. According to the prepared multifunctional electrospinning scaffold for bone regeneration, the lysophosphatidic acid nanoparticles and the zinc oxide nanoparticles are arranged on the shell layer, the deferoxamine nanoparticles are arranged on the core layer, and the electrospinning scaffold has the functions of resisting bacteria, promoting osteogenesis, promoting revascularization and the like at the same time and can be used for repairing bone tissues in a complex microenvironment.

The invention belongs to the field of a biomedical material, and specifically relates to a polylactic-acid-based bone tissue support loading icariin and deferoxamine, and a preparation and applicationof the polylactic-acid-based bone tissue support. Electrospinning technique is adopted to prepare a polylactic acid micrometer fiber support, which is then modified with a polydopamine layer, and finally, polydopamine is used for synergetic fixing of icariin and deferoxamine to the support. Through utilization of polydopamine, the hydrophilic performance, mechanical properties and cell affinity of the support are improved, and through cooperation of icariin and deferoxamine, the ossification performance and hematopoietic performance of the support are greatly improved. Through further adoption of thermally-induced phase separation, a chitosan nanometer fiber net is compounded on the polylactic acid micrometer fiber support, and based on the composite nanometer fiber net, polydopamine, icariin and deferoxamine are used for modification. The mechanical property of the support is obviously improved, which is beneficial for forming vasoganglion. The used materials are cheap, the adopted electrospinning and thermally induced phase separation technology are simple, and the performance of the material is easy to regulate, so that the support is suitable for industrialization.

The invention provides a kind of nanometer particles with iron chelators encapsulated in amphiphilic polymers and a preparation method and application thereof. The nanometer particles are formed in the mode that water-soluble chelators are encapsulated in amphiphilic polymers. According to the method, the amphiphilic polymers serve as carriers, and the nanometer particles with iron chelators encapsulated in amphiphilic polymers are obtained through a multiple emulsion method. The obtained nanometer particles are stable, the half-life period of the iron chelators in blood circulation in vivo is prolonged, the iron chelators are transported to target organs in a targeting manner, nanometer drugs containing the nanometer particles with iron chelators encapsulated in amphiphilic polymers can be used for treating iron-overloaded diseases, the iron chelators release slowly so that deferoxamine can metabolize in a human body, more iron chelators can enrich in viscera, the curative effect of the drugs is improved, the toxic and side effect on cells is reduced, and the iron chelators can remove iron in cells more efficiently.

The subject invention involves a method of extending the life span of mammals by reducing free radical damage in mammals wherein the method comprises administering to a mammal a composition comprising a safe and effective amount of a compound selected from 1-phenyl-1,2-propanedione-2-oxime, benzoylacetone, piroctone, 2-furildioxime, 2-furilmonoxime, diethyldithiocarbamic acid, deferoxamine and 1,2-dimethyl-3-hydroxy-pyrid-4-one, or a pharmaceutically acceptable salt thereof, or mixtures of the subject compounds and/or their salts.

Methods for preconditioning and/or providing neuroprotection to the animal central nervous system against the effects of Huntington's disease. Therapeutic agents are administered to the upper third of the nasal cavity to bypass the blood-brain barrier and access the central nervous system directly to avoid unwanted and potentially lethal side effects. Therapeutic agents include those substances that interact with iron and/or copper such as iron chelators, copper chelators, and antioxidants. A particular example of such therapeutic agents is the iron chelator deferoxamine (DFO). An effective amount of DFO may be administered to the upper third of the nasal cavity of a patient at risk for, or diagnosed with Huntington's disease. The effective amount of DFO is delivered directly to the patient's central nervous system for preconditioning, preventing and/or treating Huntingon's disease.

The invention discloses a polyethylene glycol modified iron ionic chelator and a preparation method thereof. The iron ionic chelator is prepared from derivatives of polyethylene glycol with good biocompatibility and deferoxamine. The preparation method comprises the step of preparing the polyethylene glycol modified iron ionic chelator by covalent binding of carboxylated polyethylene glycol monomethyl ether or formylated polyethylene glycol monomethyl ether with deferoxamine. Compared with deferoxamine, the iron ionic chelator has the advantages of long action and low toxicity, and has potential application value in treatment of iron overload related diseases.

The invention provides application of deferoxamine to preparation of medicine for preventing and/or treating tumor, and relates to the technical field of tumor science. According to the application ofdeferoxamine to the preparation of medicine for preventing and/or treating the tumor, the dose form of the medicine is an injection or a tablet; the tumor is glioma or human lung carcinoma cells. Inthe medicine, 125 to 500 mumol/L of deferoxamine and 100 mumol/L of temozolomide are contained. Through experiment methods, the result proves that the treatment effect of the temozolomide on the glioma or human lung carcinoma cells can be enhanced; the effect of cooperating with temozolomide to killing glioma or human lung carcinoma cells is achieved; the killing effect of the temozolomide on theglioma or human lung carcinoma cells can be enhanced. The deferoxamine and the temozolomide are prepared into medicine used for preventing and/or treating the glioma or human lung carcinoma cells; thetreatment effect of the temozolomide on the brain glioma or human lung carcinoma can be improved.

The invention refers to an injectable antioxidant formulation for intravenous use comprising sodium ascorbate in high dosage as a first antioxidant agent, N-acetyl cysteine as a second oxidant agent and deferoxamine as an iron chelating agent, plus pharmaceutically acceptable excipients. And an administration method of said formulation that results in a synergic and improved effect to prevent injury due to reperfusion in an organ. In particular, to prevent injury due to early and late reperfusion in patients diagnosed with acute myocardium infarction and indication of primary coronary angioplasty. The invention further refers to the use of the formulation to prevent injury due to reperfusion in patients with acute myocardium infarction, subjected to primary coronary angioplasty.

The invention develops a deferoxamine derivative with bone affinity, a preparation method and application thereof. More specifically, the invention provides a compound with a structure shown as formula (1) and its pharmaceutically acceptable salt, ester, amide, acyl halide, hydrate or solvate. The invention also provides a preparation method of the compound shown as formula (1) and application thereof in preparation of drugs for treatment of osteoporosis, osteonecrosis, delayed union or nonunion and bone defect. (formula I).

The invention belongs to the technical field of radiopharmaceutical labeling, and particularly relates to a synthesis method of ferrioxamine succinimide activated ester and an application of saflufenacil succinimide activated ester in preparation of radiopharmaceutical. According to the invention, deferoxamine (DFO) is used as a raw material to synthesize the ferrioxamine succinimide activated ester. The activated ester can be subjected to an amide condensation reaction with drug molecules with primary amino groups under a mild condition to generate an iron oxadiazon conjugate, and then ferricions are removed by a metal chelating agent through a competitive reaction to obtain a deferoxamine conjugate. The invention also relates to the use of the radiolabeled deferoxamine conjugate as an imaging agent and a therapeutic agent, by using medical radionuclides (such as 89Zr, 68Ga, 67Ga, 177Lu, 111In, 90Y) to efficiently label the deferoxamine conjugate, the generated labeled drug can be used for living PET imaging, SPECT imaging or radiotherapy.

Modified hydrophilic carbon clusters (HCCs), poly(ethylene glycol)-hydrophilic carbon clusters (PEG-HCCs) and similarly structured materials like graphene quantum dots (GQDs), PEGylated GQDs, small molecule antioxidants, and PEGylated small molecule antioxidants. These materials have been modified with an iron chelating moiety, deferoxamine, or a similar chelating moiety. By exploiting common binding sites, the carbon nanostructure facilitates intracellular transport including in mitochondria, reduces oxidative breakdown of the chelator moiety prior to treatment, and reduces both the cause and consequences of metal induced oxidative stress within the body thus providing a novel form of therapy for a range of oxidative and metal-related toxicities. Graphenic materials can be used for the treatment of acute and chronic mitochondrial electron transport chain dysfunction.

The invention discloses a stem cell scaffold applied to an iron overload region. The stem cell scaffold is a double-layered keratin gel cell having a concentric structure; the stem cell scaffold is composed a low-molecular weight keratin hydrogel outer layer coated with deferoxamine and a high-molecular weight keratin hydrogel inner layer wrapped with stem cells and trophic factors; and the stem cell scaffold is the double-layer concentric structure, the inner layer provides cell growth, and the outer layer eliminates the unfavorable environment, so cell growth is improved, the survival rate is increased, and the stem cell scaffold achieves a higher cell survival rate and a better effect than traditional transplanted cells after cerebral hemorrhage. The double-layered keratin gel cell scaffold is injected into the cerebral hemorrhage site in order to rapidly adsorb residual overload iron ions surrounding hematoma tissues by the adsorption effect of gel and release embedded drugs for chelating the iron ions, so the iron overload is eliminated; and the transplanted stem cells provide a neuroprotection effect, and can be differentiated into neurons and glial cells to repair damaged parts.